COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Balloon Prophylaxis of Aneurysmal Vasospasm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00282893
Recruitment Status : Completed
First Posted : January 27, 2006
Last Update Posted : February 15, 2017
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
The purpose of this study is to determine if early transluminal ballooning of the major cerebral arteries prevents severe vasospasm and improves neurological outcome in patients with Fisher Grade III aneurysmal subarachnoid hemorrhage.

Condition or disease Intervention/treatment Phase
Aneurysm Vasospasm Procedure: transluminal ballooning Other: currently existing therapies for the treatment of vasospasm Phase 2

Detailed Description:

Aneurysmal subarachnoid hemorrhage (SAH) afflicts over 30,000 patients a year in the United States. Fifteen percent of those who survive the initial bleeding die or suffer disabilities because of delayed ischemic deficit (stroke) due to vasospasm. Vasospasm is a condition in which the arteries in the brain constrict, not allowing sufficient blood flow and oxygenation. Research on the pharmacological prevention and treatment of vasospasm has resulted in only minimal improvement for this problem.

Transluminal ballooning is a procedure that opens blood vessels, allowing blood flow and oxygen to get to the brain more easily. Researchers believe that this dilation of the blood vessels lasts for at least 7 days. This procedure is used to treat severe vasospasm although it is not commonly used to prevent vasospasm. The purpose of this trial is to find out if this procedure, performed immediately after the aneurysm is secured, prevents spasm in the brain and improves patient outcome.

Eligible SAH patients whose aneurysm has been repaired by neurosurgical or endovascular procedure and who are enrolled in the study will be randomized to receive either the prophylactic transluminal ballooning procedure or to receive standard care, which includes currently existing therapies for the treatment of vasospasm.

Participants will be asked to return for follow-up examinations at 3 and 6 months to evaluate recovery using a standardized outcome scale.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Balloon Prophylaxis of Aneurysmal Vasospasm
Study Start Date : October 2000
Actual Primary Completion Date : September 2006
Actual Study Completion Date : December 2006

Arm Intervention/treatment
Experimental: pTBA
Prophylactic Transluminal Ballooning Angioplasty
Procedure: transluminal ballooning
Active Comparator: Control
currently existing therapies for the treatment of vasospasm
Other: currently existing therapies for the treatment of vasospasm

Primary Outcome Measures :
  1. Dichotomized Glasgow Outcome Scale (GOS)assessed at 3 months by a blinded evaluator

Secondary Outcome Measures :
  1. Dichotomized GOS at 6 months, assessment at 3 and 6 months of: five-point GOS; GOS - Extended (GOSE), occurrence of delayed ischemic deficit (DID), the incidence of severe vasospasm as detected by Transcranial Doppler (TCD) Ultrasonography (mean blood f

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   17 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Fisher grade III hemorrhage
  • Documented ruptured cerebral aneurysm via angiography, CT angiogram or any other acceptable neuroradiologic means
  • Ruptured aneurysm(s) secured
  • Ballooning available < 96 hours post SAH

Exclusion Criteria:

  • Vasospasm prior to randomization
  • Interventionalist unavailable
  • Patient outside the 96 hour window for ballooning
  • Enrolled in competing trial
  • Unsecured aneurysms (symptomatic or asymptomatic) that are in the location where the ballooning procedure would occur
  • Medical conditions known that would effect mortality / morbidity
  • Severe Cerebrovascular atherosclerosis
  • > 16 years old.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00282893

Layout table for location information
United States, California
Coordinating Center: University of California, Davis Medical Center, Department of Neurological Surgery
Sacramento, California, United States, 95817
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-2380
United States, Washington
University of Washington - Harborview Medical Center
Seattle, Washington, United States, 98014
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5B-1A6
University Medical Center Utrecht, Trialbeureau Neurodivisie, Heidelberglaan 100
Utrecht, Netherlands, 3584 CX
Sponsors and Collaborators
University of California, Davis
National Institute of Neurological Disorders and Stroke (NINDS)
Layout table for investigator information
Principal Investigator: Jan Paul Muizelaar, MD, PhD Professor and Chairman, Department of Neurological Surgery, University of California, Davis
Principal Investigator: Jonathan Hartman, MD Interventional Neuroradiologist, University of California, Davis
Principal Investigator: Marike Zwienenberg, MD University of California, Davis
Publications of Results:
Layout table for additonal information
Responsible Party: University of California, Davis Identifier: NCT00282893    
Other Study ID Numbers: 200311385
R01NS038484 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2006    Key Record Dates
Last Update Posted: February 15, 2017
Last Verified: March 2014
Keywords provided by University of California, Davis:
subarachnoid hemorrhage
transluminal ballooning
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases